NCT02058563 - Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older | Biotech Hunter

Enrollment

996

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

May 24, 2015

Study Completion Date

September 17, 2015

Conditions

RubellaMumpsMeasles

Interventions

BIOLOGICAL

Priorix®

1 dose administered as a subcutaneous (SC) injection.

BIOLOGICAL

Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine

1 dose administered subcutaneously.

Trial Locations (17)

33144

GSK Investigational Site, Miami

33176

GSK Investigational Site, Miami

35211

GSK Investigational Site, Birmingham

45249

GSK Investigational Site, Cincinnati

50106

GSK Investigational Site, Tartu

55435

GSK Investigational Site, Edina

60654

GSK Investigational Site, Chicago

63141

GSK Investigational Site, St Louis

78229

GSK Investigational Site, San Antonio

85224

GSK Investigational Site, Chandler

Unknown

GSK Investigational Site, Mesa

851 01

GSK Investigational Site, Bratislava

026 01

GSK Investigational Site, Dolný Kubín

929 01

GSK Investigational Site, Dunajská Streda

036 01

GSK Investigational Site, Martin

034 01

GSK Investigational Site, Ružomberok

953 01

GSK Investigational Site, Zlaté Moravce